Dr. Davies on Future Research Directions With Isatuximab in Multiple Myeloma

Partner | Cancer Centers | <b>Perlmutter Cancer Center at NYU Langone</b>

Faith Davies, MD, discusses future research directions with isatuximab in the treatment of patients with multiple myeloma.

Faith Davies, MD, a professor in the Department of Medicine and director of the Clinical Myeloma Program at NYU Langone Health’s Perlmutter Cancer Center, discusses future research directions with isatuximab (Sarclisa) in the treatment of patients with multiple myeloma.

Based on the data with isatuximab that have read out from the phase 3 IKEMA (NCT03275285) and ICARIA-MM (NCT02990338) studies, which examined the agent in combination with carfilzomib (Kyprolis) plus dexamethasone, and pomalidomide (Pomalyst) plus dexamethasone, respectively, the drug has shown to have clinical benefit, according to Davies. As such, moving forward, isatuximab could potentially be utilized in combination with other approved multiple myeloma treatments, Davies says. Specifically, data of its use in the newly diagnosed setting is highly anticipated, as that is an area of need where the agent could be utilized, Davies notes. 

Moreover, preliminary data on the use of isatuximab in newly diagnosed, high-risk patients with multiple myeloma were presented from a research group in Germany, and response rates have been encouraging, Davies adds. Moreover, other clinical data with the agent is expected to read out soon, and will be important moving forward, Davies concludes.